Purpose: To assess the prognostic significance of the nuclear receptor binding SET protein 2 (NSD2), a co-activator of the NFkB-pathway, on tumour progression in patients with advanced prostate cancer (PCa).Methods: We retrospectively assessed NSD2 expression in 53 patients with metastatic and castration-resistant PCa. Immunohistochemical staining for NSD2 was carried out on specimen obtained from palliative resection of the prostate. Univariable and multivariable analyses were performed to assess the association between NSD2 expression and PCa progression.Results: Of the 53 patients, 41 had castration-resistant PCa and 48 men had metastases at time of tissue acquisition. NSD2 expression was increased in tumour specimen from 42 patients (79.2%). In univariable Cox regression analyses, NSD2 expression was associated with PSA progression, progression on imaging and overall survival (p = 0.04, respectively). In multivariable analyses, NSD2 expression did not retain its association with these endpoints.Conclusions: NSD2 expression is abnormal in almost 80% of patients with advanced PCa. Expression levels of this epigenetic regulator are easily detected by immunohistochemistry while this biomarker exhibited prognostic value for PCa progression and death in univariable analysis. Further studies on NSD2 involvement in PCa proliferation, progression, metastasis and resistance mechanisms are needed.

Judith Stangl-Kremser

Ursula Lemberger

Melanie R. Hassler

Nathalie Garstka

Bernhard Grubmüller

Andrea Haitel

Dmitry V. Enikeev

Petr V. Glybochko

Gero Kramer

Martin Susani

Shahrokh F. Shariat

Biomarkers

《生物标志物》杂志汇集了快速发展的生物标志物研究领域的各个方面，在一个重要来源中涵盖了它们的各种用途和应用。生物标志物为在生物标志物研究的所有领域交流思想和概念提供了一个重要论坛。接受四个主要领域的高质量论文，特别鼓励描述新生物标志物及其后续验证的手稿：• 疾病的生物标志物• 暴露的生物标志物• 反应的生物标志物• 易感性的生物标志物手稿可以描述在人体或其他动物体内或其他动物中测量的生物标志物。体外。生物标志物将考虑发布来自人群易感性生物标志物研究的负面数据。

The journal "Biomarkers" encompasses various aspects of the rapidly evolving field of biomarker research, covering a wide range of uses and applications. It serves as an important forum for exchanging ideas and concepts in all areas of biomarker research. We accept high-quality papers from four main areas, particularly encouraging manuscripts that describe new biomarkers and their subsequent validation: • Biomarkers of disease • Biomarkers of exposure • Biomarkers of response • Biomarkers of susceptibility. Manuscripts may describe biomarkers measured in humans or other animals, as well as in vitro studies. We also welcome submissions of negative data from studies on population susceptibility biomarkers.

《Biomarkers》杂志汇集了生物标志物研究领域的各个方面，涵盖了其多种用途和应用，成为一个重要的交流平台。我们接受来自四个主要领域的高质量论文，特别鼓励描述新生物标志物及其后续验证的手稿，包括：• 疾病生物标志物 • 暴露生物标志物 • 反应生物标志物 • 易感性生物标志物。手稿可以涉及在人体或其他动物体内，或体外测量的生物标志物。此外，我们也欢迎来自人群易感性生物标志物研究的负面数据的投稿。

The prognostic impact of tumour NSD2 expression in advanced prostate cancer

NSD2 expression is abnormal in almost 80% of patients with advanced PCa and expression levels of this epigenetic regulator are easily detected by immunohistochemistry while this biomarker exhibited prognostic value for PCa progression and death in univariable analysis.

Category	Quartile
医学	4
医学, 生物工程与应用微生物	4
医学, 毒理学	4

The prognostic impact of tumour NSD2 expression in advanced prostate cancer

ivySCI AI Smartly Parses PDF, Answers Researchers' Questions, and Helps You Understand Papers in Seconds

Journal Info